Holen Sie sich die Stockscreener-App
289.04
1.31%
-3.85
Handel nachbörslich:
289.04
Schlusskurs vom Vortag:
$292.89
Offen:
$293.08
24-Stunden-Volumen:
895.77K
Relative Volume:
1.40
Marktkapitalisierung:
$20.33B
Einnahmen:
$2.36B
Nettoeinkommen (Verlust:
$236.10M
KGV:
87.96
EPS:
3.286
Netto-Cashflow:
$382.50M
1W Leistung:
+2.16%
1M Leistung:
-1.75%
6M Leistung:
-2.83%
1J Leistung:
+6.91%
1-Tages-Spanne:
$280.52
$294.04
1-Wochen-Bereich:
$278.79
$299.80
52-Wochen-Spanne:
$230.05
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Vergleichen Sie PODD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
289.04 | 20.60B | 2.36B | 236.10M | 382.50M | 3.286 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Bernstein Lowers Price Target for Insulet (PODD) to $380, Mainta - GuruFocus
Precision Medicine and the Tubeless Revolution: An In-Depth Look at Insulet Corporation (PODD) - FinancialContent
Here's Why Insulet (PODD) is a Strong Growth Stock - Yahoo Finance
Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $365 From $388, Maintains Buy Rating - MarketScreener
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 - BioSpace
Is Insulet Corporation stock a bargain at current levelsJuly 2025 Market Mood & Daily Growth Stock Tips - ulpravda.ru
Will Insulet Corporation stock outperform value stocksEarnings Trend Report & Reliable Breakout Stock Forecasts - ulpravda.ru
Trading Recap: Why hedge funds are buying Insulet Corporation stockMarket Rally & Free AI Powered Buy and Sell Recommendations - ulpravda.ru
Institution Moves: What margin trends mean for Insulet Corporation stockGap Up & Safe Entry Trade Reports - ulpravda.ru
Pullback Watch: What margin trends mean for Insulet Corporation stockWeekly Trend Recap & Stock Market Timing Techniques - ulpravda.ru
Can Insulet Corporation stock hit record highs againTrade Entry Report & Technical Confirmation Alerts - ulpravda.ru
What Provides InsuletCorp. (PODD) With a Durable Competitive Advantage? - Insider Monkey
Can Insulet Corporation (GOV) stock resist broad market declinesWeekly Trading Summary & High Accuracy Investment Signals - ulpravda.ru
Insulet’s Human‑First Omnipod 5 CES Debut Might Change The Case For Investing In Insulet (PODD) - Sahm
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health - Business Wire
Declining Stock and Solid Fundamentals: Is The Market Wrong About Insulet Corporation (NASDAQ:PODD)? - Yahoo Finance
How Insulet Corporation (PODD) Affects Rotational Strategy Timing - Stock Traders Daily
Is it the Right Time to Add Insulet Stock to Your Portfolio? - Yahoo Finance
Will BluEnergies Ltd 66E stock benefit from infrastructure billJuly 2025 Update & Growth Focused Entry Reports - moha.gov.vn
Braun Stacey Associates Inc. Makes New Investment in Insulet Corporation $PODD - MarketBeat
Insulet Corporation $PODD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Insulet (PODD) - Zacks Investment Research
Insulet Corporation $PODD Shares Sold by Ayrshire Capital Management LLC - MarketBeat
From Edwards to Insulet: Three key medical device cases of 2025 - Life Sciences Intellectual Property Review
Insulet Corporation (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Swedbank AB Buys 5,000 Shares of Insulet Corporation $PODD - MarketBeat
Osaic Holdings Inc. Purchases 5,309 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Has $25.11 Million Stake in Insulet Corporation $PODD - MarketBeat
3 Reasons Growth Investors Will Love Insulet (PODD) - sharewise.com
Insulet Corporation $PODD Holdings Decreased by Squarepoint Ops LLC - MarketBeat
Insulet Corporation $PODD Shares Acquired by Munro Partners - MarketBeat
Insulet Corp. Stock Underperforms Tuesday When Compared To Competitors - 富途牛牛
Insulin Delivery Devices Market Outlook: Market to Reach US$ - openPR.com
Insulet Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Patton Fund Management Inc. Buys 13,972 Shares of Insulet Corporation $PODD - MarketBeat
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corporation's (NASDAQ:PODD) Business Is Yet to Catch Up With Its Share Price - 富途牛牛
Truist Cuts Insulet (PODD) PT but Maintains Buy as Top MedTech Pick for 2026 - Insider Monkey
Is Insulet Fairly Priced After Its Strong Run and High Earnings Multiple in 2025? - simplywall.st
Voya Investment Management LLC Has $19.59 Million Stock Holdings in Insulet Corporation $PODD - MarketBeat
(PODD) Risk Channels and Responsive Allocation - Stock Traders Daily
Tubeless Insulin Pumps Market Size, Share, Trends | Top - openPR.com
Congress Asset Management Co. Acquires 9,976 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Stock Analysis: A 30% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
Why Insulet Corporation (GOV) stock is a strong analyst pick2025 Technical Patterns & AI Powered Market Entry Strategies - Улправда
Perpetual Ltd Sells 5,898 Shares of Insulet Corporation $PODD - MarketBeat
Should Insulet’s (PODD) Expanded Pod Recycling Effort Reframe Its Long‑Term Sustainability Edge? - Yahoo Finance UK
Guidance Update: Can Insulet Corporation (GOV) stock sustain revenue momentum2025 Growth vs Value & Weekly Breakout Watchlists - moha.gov.vn
Insulet appoints PwC as new auditor for 2026, replaces Grant Thornton By Investing.com - Investing.com Nigeria
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):